Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.36 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3373503 | 1.00 | CYP3A4 (0.49) | CYP3A4CTSBP2RX3KDM4ENPC1 | |
| SCHEMBL8142622 | 0.92 | CYP3A4 (0.48) | CYP3A4CTSBP2RX3KDM4ENPC1 | |
| SCHEMBL3671701 | 0.92 | CYP3A4 (0.48) | CYP3A4CTSBP2RX3KDM4ENPC1 | |
| SCHEMBL10228383 | 0.92 | CYP3A4 (0.48) | CYP3A4CTSBP2RX3KDM4ENPC1 | |
| SCHEMBL375051 | 0.92 | CYP3A4 (0.48) | CYP3A4CTSBP2RX3KDM4ENPC1 | |
| SCHEMBL12558060 | 0.91 | CYP3A4 (0.47) | CYP3A4CTSBP2RX3KDM4ENPC1 | |
| SCHEMBL3375479 | 0.86 | CYP3A4 (0.65) | CYP3A4CTSBP2RX3KDM4EROCK2 | |
| SCHEMBL16318729 | 0.85 | CCNT1 (0.42) | CYP3A4CTSBP2RX3CCNT1CDK9 | |
| SCHEMBL16318728 | 0.85 | CCNT1 (0.42) | CYP3A4CTSBP2RX3CCNT1CDK9 | |
| SCHEMBL8195379 | 0.85 | CYP3A4 (0.42) | CYP3A4CTSBP2RX3KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| WO-2009005677-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186869-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | CYP3A4 1770/4885CTSB 630/4885P2RX3 2759/4885 |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CYP3A4 1770/4885CTSB 630/4885P2RX3 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.